Venous Thromboembolism - Drug Pipeline Landscape, 2023

Venous Thromboembolism - Drug Pipeline Landscape, 2023

Venous thrombosis occurs due to the blockage of the veins caused by a thrombus (blood clot). A common form of venous thrombosis is deep vein thrombosis (DVT), this occurs when blood clots in the deep veins. If a blood clot breaks off (embolizes) and flows to the lungs to lodge, then it becomes a pulmonary embolism (PE). The conditions including DVT only, DVT with PE, and PE only altogether referred as "Venous Thromboembolism".

Venous thromboembolism is caused by a combination of venous stasis and hypercoagulability, and to a lesser extent endothelial damage and activation also plays a crucial role. The most common causes are injury and infections. In some cases, it might be due to medical intervention including surgery, chemotherapy, inserting IV or catheter.

Venous thromboembolism can be diagnosed by the initial screening through the signs and symptoms of the condition. DVT are diagnosed through blood tests, vascular ultrasound, MR venography and contrast venography. PE can be diagnosed through pulse oximetry, chest X-ray, CT pulmonary angiography and pulmonary angiogram.

Venous Thromboembolism is diagnosed through CT pulmonary angiography - also called CT pulmonary embolism which creates 3dimensional images that can detect abnormalities such as pulmonary embolism within the arteries in the lungs.

Venous thromboembolism treatment goals are to prevent clot from getting bigger, from breaking loose and traveling to the lungs and chances of another DVT. Medication includes anticoagulants, thrombolytics, inferior vena cava filters and superficial venous thrombosis. In rare cases, a surgical procedure is included to remove the clot. Thrombectomy - removal of clots in DVT patients and embolectomy – removal of blockages caused by the clots in in the lungs in PE patients.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Venous Thromboembolism treatment such as DD217, abelacimab, milvexian, EP-7041, and others. Key players involved in the development of therapies to treat venous thromboembolism are Anthos Therapeutics, Bristol-Myers Squibb, Daiichi Sankyo, and others. Five drugs are under Phase III clinical trials and five drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development. In Sep 2022, Anthos Therapeutics received Fast Track Designation issued by the US FDA for abelacimab.

Report Highlights

Global Insight Service's, Venous Thromboembolism - Drug Pipeline Landscape, 2023 report provides an overview of the Venous Thromboembolism pipeline drugs. This report covers detailed insights on Venous Thromboembolism drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Venous Thromboembolism pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation. Show more